Rhythm Pharmaceuticals (RYTM) Invested Capital: 2016-2025
Historic Invested Capital for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to $154.4 million.
- Rhythm Pharmaceuticals' Invested Capital rose 1276.49% to $154.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $154.4 million, marking a year-over-year increase of 1276.49%. This contributed to the annual value of $23.3 million for FY2024, which is 86.29% down from last year.
- Rhythm Pharmaceuticals' Invested Capital amounted to $154.4 million in Q3 2025, which was up 1,998.81% from -$8.1 million recorded in Q2 2025.
- Over the past 5 years, Rhythm Pharmaceuticals' Invested Capital peaked at $380.9 million during Q1 2021, and registered a low of -$8.1 million during Q2 2025.
- Over the past 3 years, Rhythm Pharmaceuticals' median Invested Capital value was $61.6 million (recorded in 2024), while the average stood at $97.4 million.
- Examining YoY changes over the last 5 years, Rhythm Pharmaceuticals' Invested Capital showed a top increase of 1,276.49% in 2025 and a maximum decrease of 120.66% in 2025.
- Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Invested Capital stood at $284.2 million in 2021, then declined by 7.00% to $264.3 million in 2022, then tumbled by 35.76% to $169.8 million in 2023, then plummeted by 86.29% to $23.3 million in 2024, then skyrocketed by 1,276.49% to $154.4 million in 2025.
- Its Invested Capital stands at $154.4 million for Q3 2025, versus -$8.1 million for Q2 2025 and $20.5 million for Q1 2025.